|
WO2008118946A1
|
|
Methods and compositions using certain phenolic derivatives for the treatment of diabetes
|
|
EP1931355A2
|
|
Methods for reducing platelet activation and for the treatment of thrombotic events
|
|
AU2006202461A1
|
|
Compositions and methods for the inhibition of the expression of VCAM-1
|
|
CN101203487A
|
|
Process for the separation of probucol derivatives
|
|
AU2006240083A1
|
|
Process for the separation of probucol derivatives
|
|
WO2006031806A2
|
|
2-thiopyrimidinones as therapeutic agents
|
|
CA2571589A1
|
|
Compounds and methods for treating diabetic vascular diseases
|
|
WO2006004903A2
|
|
1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
|
|
ZA200503708B
|
|
1,3-Bis-(substituted-phenyl)-2-propen-1-ones and their use to treat VCAM-1 mediated disorders
|
|
WO2005112914A2
|
|
Phenolic antioxidants for the treatment of disorders including arthritis, asthma and coronary artery disease
|
|
WO2005102323A2
|
|
Process of preparing esters and ethers of probucol and derivatives thereof
|
|
US2005120396A1
|
|
Human MEKK1 protein and nucleic acid molecules and uses therefor
|
|
WO2004108094A2
|
|
Sulfonamide-substituted chalcone derivatives and their use to treat diseases
|
|
CA2512980A1
|
|
Process of preparing esters and ethers of probucol and derivatives thereof
|
|
WO2004056727A2
|
|
Process of making chalcone derivatives
|
|
EP1551791A1
|
|
Novel salt forms of poorly soluble probucol esters and ethers
|
|
US2004019918A1
|
|
Human MEKK2 protein and nucleic acid molecules and uses therefor
|
|
UA81617C2
|
|
Chalcone derivatives and their use
|
|
HU0500165A2
|
|
Chalcone derivatives and their use to treat diseases
|
|
AU2002361811A1
|
|
1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
|
